SAB生物治疗公司在2025年EASD会议上展示了SAB-142的I期数据,显示健康志愿者中淋巴细胞暂时下降SAB Biotherapeutics Presents Phase:Data on SAB-142 Showing Transient Lymphocyte Declines in Healthy Volunteers at 2025 EASD Conference

动脉网
Sep 18

by Mark Chiang马克·蒋Share To分享到At the 2025 European Association for the Study of Diabetes (EASD) conference in Vienna, SAB Biotherapeutics unveiled Phase I clinical trial data for SAB-142, a fully human...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10